Estrogen Therapy Lowers Parkinson Risk
Researchers have found that women who had one or both ovaries removed before menopause face an increased long-term risk of Parkinson’s disease compared to women who retained their ovaries.
Since ovaries are responsible for estrogen production, estrogen replacement therapy may be warranted for this population.
This study, the largest of its kind, appears in the online edition of the journal Neurology, the medical journal of the American Academy of Neurology.
While further studies are needed to validate these findings and clarify their clinical implications, this Mayo Clinic research is among the first to suggest that there is an age-related therapeutic window of opportunity for estrogen replacement therapy.
Before age 50, estrogen replacement therapy may, in fact, be beneficial for the brain function of women who have their ovaries removed. This large study involved reviews of medical records and follow-up interviews with approximately 4,600 women.
Prior to this Mayo Clinic report, there was limited or conflicting clinical and epidemiological evidence about estrogen’s ability to protect brain functioning in women — referred to as neuroprotection.
The Mayo research results show that not only did women who had one or both ovaries removed before menopause have an increased risk for Parkinson’s disease or parkinsonism compared to other women, but that the risk increased the younger the woman was at ovary removal.
“The decision to remove the ovaries for a benign ovarian disease or for the prevention of ovarian cancer, and the decision to take estrogen treatment for a number of years after the removal of the ovaries, must be individualized for each woman,” explains Walter Rocca, M.D., a Mayo Clinic neurologist, epidemiologist and lead author of the study.
“The surgery has expected advantages and disadvantages. Our findings support the concept that there is a window of therapeutic opportunity before the approximate age of naturally occurring menopause, 50 to 55, when the benefits of neuroprotection outweigh the risks of side effects of estrogen therapy.”
Based on the results of other studies, the Mayo Clinic researchers also say that after age 55 or 60 the balance of advantages and disadvantages from starting estrogen treatment is still somewhat uncertain, and the risk of side effects, such as increased cancers or strokes, from estrogen therapy may increase progressively with age.
“There is strong evidence from other studies that starting treatment with estrogen after age 60 to 65 is not recommended,” Dr. Rocca says.
Implications for Patient Care
A woman considering ovary removal should discuss these findings with her physician prior to the surgery to consider the long-term implications and the possible strategies for estrogen treatment following the surgery.
“In view of this new information, careful individualized counseling is necessary to help women make informed decisions.” says Bobbie Gostout, M.D., a Mayo Clinic gynecological and obstetrical surgeon.
“When oophorectomy (ovary removal) is indicated in a young woman, it is important to carefully educate her regarding estrogen replacement. Unless clear contraindications are present, most women should be advised to start estrogen therapy after the surgery and to continue it until approximately age 50 if the ovaries must be removed.”
Dr. Gostout adds that a more challenging situation arises when only one ovary has to be removed in a young woman. “Traditionally, we’ve taught that the remaining ovary compensates in hormone production,” Dr. Gostout says.
“The findings in this study tell us to carefully monitor such women for signs of low estrogen, but as of yet we don’t know when and how to compensate for the hormone changes when a single ovary is removed.”
Source: Mayo Clinic
Nauert PhD, R. (2007). Estrogen Therapy Lowers Parkinson Risk. Psych Central. Retrieved on September 2, 2015, from http://psychcentral.com/news/2007/08/31/estrogen-therapy-lowers-parkinson-risk/1215.html